Guardant Health Inc logo

Guardant Health Inc(GH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
5-STAR RATING
PASS
LAST CLOSE
$151.7
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GH

11/13/2026: GH (5-star) is currently NOT-A-BUY. Pass it for now.

Guardant Health Inc is a commercial-stage precision oncology company specializing in non-invasive blood-based cancer diagnostics and screening. Its primary strengths lie in its proprietary liquid biopsy technology, led by tests like Guardant360 and the FDA-approved Shield colorectal screening test, which deliver solid gross margins and robust revenue growth. The core investment opportunity rests on capturing a massive primary care market through accessible cancer screening. However, key risks include ongoing net losses, heavy reliance on reimbursement payors, and intense competition from rivals. The stock suits growth-oriented investors willing to monitor regulatory updates, reimbursement milestones, and progress toward profitability.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitRapid top-line revenue expansion and massive addressable markets in cancer screening align well with growth strategies.
Momentum investorStrong fit while signal remains positiveStrong quarterly volume reports and raising guidance can spark sharp positive momentum shifts.
Value investorWeak fitThe company currently reports net losses and trades on forward growth potential rather than traditional value metrics.
Dividend investorWeak fitGuardant Health does not pay dividends, retaining all earnings for business reinvestment.
Low-risk investorWeak fitHigh volatility and unprofitability present execution and regulatory risks unsuited for low-risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech and diagnostic stocks frequently experience sharp price swings based on clinical data releases and reimbursement news.
Valuation riskMedium / highValuations heavily discount future cash flows from emerging screening products, leaving little room for commercial execution errors.
Competition risk (Exact Sciences, Natera, Tempus AI)HighAggressive rivals are scaling rival screening, MRD, and tumor profiling platforms that could capture market share.
Business qualityStrongThe company possesses high gross margins and proprietary technology protecting its core liquid biopsy franchise.
Dividend incomeLow / noneNo dividends are distributed as cash is prioritized for R&D and commercial scaling.
Execution riskHighSuccessfully scaling primary care adoption for Shield requires overcoming entrenched screening habits and securing broad insurance coverage.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 20.52B USD
Price to earnings Ratio -
1Y Target Price 200.76
Price to earnings Ratio -
1Y Target Price 200.76
Volume (30-day avg) 2.1M shares
Beta 1.66
52 Weeks Range 74.55 - 191.05
Updated Date 11/15/2026
52 Weeks Range 74.55 - 191.05
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.68

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
68.8%
Active BUY / eligible
11 / 16
30-Day BUY Count Change
0

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 66.48%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GH receives a 3-star rating, supported by solid company fundamentals, and strong analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
GH has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+4.6%) and solid revenue growth (+32.9%) are partially offset by weak cash generation (FCF margin -23.7%), weak profitability (net margin -42.4%), modest insider ownership of 4.65%.

Financial Health Rating

★★★★★
GH's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 57.8%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is GH's strongest growth driver at +32.9% FY2025 versus FY2024 (solid, 4 stars). Earnings growth (+4.6%, moderate) and free-cash-flow growth (+15.2%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 98.7% and approximately 96.5% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 4.65% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 5.63%
T. Rowe Price Associates, Inc. 4.82%
Vanguard Capital Management, LLC 4.25%
FMR Inc 4.06%
Vanguard Portfolio Management, LLC 4.03%

Unit Economics (Per $1K Revenue)

★★★★★
GH generates approximately $645 of gross profit, $-445 of operating income, and $-237 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.30%

Quantitative Style Profile

★★★★★
GH has a large-cap, liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

High VolatilityLarge / Mega Cap StabilityShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical TestsRevenues generated from processing Guardant360, Guardant Reveal, and Shield tests ordered by physicians for patient care.This is the core engine of the company, bringing in the vast majority of revenue as more doctors adopt blood-based testing.
Development ServicesCollaborations with biopharmaceutical companies to support clinical trials and companion diagnostic development.Provides stable partnership revenue and helps validate technologies alongside major drug launches.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 21.21B
Price to Sales(TTM) 16.05
Enterprise Value 21.21B
Price to Sales(TTM) 16.05
Enterprise Value to Revenue 16.58
Enterprise Value to EBITDA -5.4
Shares Outstanding 135.29M
Shares Floating 130.57M
Shares Outstanding 135.29M
Shares Floating 130.57M
Percent Insiders 4.65
Percent Institutions 98.73

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.